INKT INKT
Company Profile ↓Company Overview
INKT (INKT) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 87.8%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -11.50% |
| 6 Months: | +4.28% |
| 3 Months: | +1.39% |
| 1 Month: | +10.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 87.8%.
CONS
- Trading 33.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.53M | 3.69M | 2.99M | 3.28M | 2.88M |
| Operating Income | - | - | -5.92M | -3.01M | -5.61M | -13.38M | -7.37M | -7.70M | -7.99M | -5.85M | -6.34M | -5.22M | -3.83M | -3.07M | -1.88M | - | -2.53M | -3.69M | -2.99M | -3.28M | -2.88M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.48M | -3.64M | -2.95M | -3.24M | -2.85M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.77M | -4.24M | -2.89M | -2.60M | -2.74M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.39M | -4.27M | -6.04M | -3.85M | -6.34M | -14.27M | -7.78M | -6.11M | -6.33M | -5.69M | -6.20M | -5.12M | -3.81M | -2.70M | -1.81M | - | -2.77M | -4.24M | -2.89M | -2.60M | -2.74M |
| Diluted EPS | - | - | - | - | -0.26 | -0.59 | -0.23 | -0.18 | -0.19 | -0.17 | -0.18 | -0.15 | -1.10 | -0.73 | -0.46 | - | -0.70 | -1.06 | -0.65 | - | -0.57 |
| R&D Expense | - | - | 2.50M | 3.10M | 3.58M | 3.33M | 5.28M | 5.88M | 6.15M | 4.19M | 4.56M | 3.43M | 2.55M | 1.84M | 540.64K | - | 1.26M | 1.84M | 1.14M | - | 1.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -14.64M | -28.36M | -30.95M | -22.92M | -11.29M | -12.64M |
| Net Income | -16.24M | -30.21M | -27.99M | -22.46M | -10.78M | -12.49M |
| Diluted EPS | - | -1.16 | -0.83 | -6.54 | -2.86 | -2.93 |
| R&D Expense | 9.51M | 13.97M | 23.12M | 15.49M | 6.34M | 5.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.56M | 40.24M | 21.47M | 4.55M | 5.72M | 14.24M |
| Total Equity | -36.33M | -53.87M | 23.78M | -401.30K | -18.06M | -19.59M | -14.23M |
| Cash & Equivalents | - | - | 38.89M | 19.64M | 3.37M | 4.58M | 13.36M |
| Current Liabilities | - | 14.22M | 16.47M | 12.68M | 11.40M | 6.96M | 13.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.34M | -12.83M | -18.87M | -15.76M | -9.56M | -5.93M |
| Investing Cash Flow | -95.21K | -248.98K | -250.05K | -73.56K | - | - |
| Financing Cash Flow | 11.11M | 49.26M | -155.60K | -407.17K | 10.82M | 14.72M |
| Capital Expenditure | -95.21K | -248.98K | -250.05K | -73.56K | - | - |
| Free Cash Flow | -8.43M | -13.08M | -19.12M | -15.84M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 30.1% | -127.1% | 6,975.1% | 124.4% | 55.1% | 87.8% |
| ROCE % | 151.4% | -119.3% | -352.2% | 334.6% | 911.2% | -1,047.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INKT
Here's Why You Should Add INKT Stock to Your Portfolio Now - TradingView
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQOTg2S1JhSWw5NGRrTjk4X0tvXzRwVWNrSHN3b1NZc0lWbGhuMHJ5U3hUTGhkTnZYT1U0RGdYbVFscmljRVctampHUHF1T3A5YW5NOExWUUVxTndGd1RhdElRYTZ2bUtHd2FsWjBnNHJEb2szZ2NmOFJWLWZIU0dkLVJlYkl5aGUybkFwS1…
Why Did INKT Stock Jump 30% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPSUh4dm5aem9FZk5jVXVERW15Q25lamtqcXVzclZJUFNxeXhIZDF1QUNpSGZpQUFhRkxaZ0Uxd0szVXNILTNFUWhIYWVPRXAyYUJteGtDd2ROdDg3R0hNbnZFbDR4ajJ0ZkozSWhfOTlHTXRKZXc3X1E2SVAyRmpCWFNROHlqLW9TSEJ5Rn…
$INKT stock is up 15% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPSXM1N21JVjJPQklucXIyN05CRWh2djJoNklxc01MYW9kWG5Nc3gzcW5WYjEzQmVWWVg1cVppUzlIeFlSUU9Ta1VIUi0tZE82ZlhIXzl6X3hRaDJ6Wkc3NmdGRC1EaE9UajVvRmwzTW5MdGNuZ010RVh1TVdwbGpfT1lZc1ZfN0Q4b3N1X0…
What date does MiNK Therapeutics, Inc.'s (INKT) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE5QWFpzVUJmVDdPa3ZRbkQ3Y09TMkJPYjZYVW1MajFSV3pUVWdCYU5fU3RlalBMM2ZqRWtrWVhkb3BWUDlRaXFibDlub1ZMT2xmNWV6S3hDZG5IOGxtaTlocWkydnlGNml6TlFv?oc=5" target="_blank">What date does MiNK The…
New cell therapy tested in Ukraine ICU for severe acute lung injury - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcDJVR1hud3BkY1hSQ3l1aGZyeGtWU1lnVWdVQ1JzYTVfRVkxbmlBaGlNQlBldXBFNHBmV1ZtWWo3LXlwLXdILU91TmRRa2t0VDViNkplRC01WXZ3SUxUQWFPdTdHcHlSXzd3eTA4MjRsWjdRT1VDU3VtT0JsS3JWSjlqU1dZQzdvTjR3Mn…
Why is Mink Therapeutics stock surging today? - Investing.com
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPMUFkMF9rWmQ0enZDUzFqd3RDVWhaZHpUelhBOGFBVzl3TW14cmc2VU9kX0ExY0g1OHFBNk9vRHI1WWJKeXNsdFA0YXBNbnNSNXJ5c2lSZ093MUQydmNNTzVfcWx6MmJMeHlTN2dMQVFnT1VNUzBtM1Vud1lseDFoMHVOeGlfQ3VfcTRTNG…
INKT — Frequently Asked Questions
What is the current share price of INKT?
As of 2026-08-05 17:25 PDT, INKT trades at $11.70 on NASDAQ/NYSE. Its 52-week range is $8.56 to $17.50.
What is the P/E ratio of INKT?
INKT trades at a trailing price-to-earnings (P/E) ratio of -3.99.
What is the return on equity (ROE) of INKT?
INKT has a return on equity (ROE) of 87.82%.
Is INKT a good stock to buy?
This page provides a data-driven analysis of INKT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.